Lexicon Pharmaceuticals, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
See more in Biomedtracker

Latest on Lexicon Pharmaceuticals, Inc.

Scrip

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

In its sixth cardiometabolic disease deal of 2025, Novo Nordisk – reportedly concerned about its standing in the obesity and diabetes space versus its nearest rival, Eli Lilly – will turn to Deep Ap

Scrip

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 
• By Andrew McConaghie

Novo Nordisk has once again demonstrated its drive to stay on top in obesity, unveiling its second licensing deal in a matter of days. It will pay $75m upfront for rights to Lexicon’s LX9851, a first-

Scrip

Lexicon’s Sunny Take Does Not Sway Investors About Phase IIb DPNP Miss

 
• By Joseph Haas

Lexicon Pharmaceuticals presented its Phase IIb data for pilavapadin (LX9211) on 3 March as a win that clarified the dosing regimen to take into Phase III in diabetic peripheral neuropathic pain (DPNP

Scrip

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

Lexicon Pharmaceuticals has an important data readout coming in the first quarter for a Phase IIb study testing pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP). If that trial r